Caitlyn Jenner Women's HRT: Compounded vs. Branded, What's Likely

What Caitlyn Jenner Has Said Publicly About Her Hormone Therapy

Caitlyn Jenner confirmed she began feminizing hormone therapy as part of her gender transition, which she discussed in detail in her 2015 ABC interview with Diane Sawyer and her memoir The Secrets of My Life (2017). She has not released specific lab values or brand names publicly. That leaves clinicians and journalists working from population-level prescribing data and guideline-based inference.

What "Going Public" Actually Tells Clinicians

Jenner has described a process that began well before her public transition, which suggests she had been consulting with physicians familiar with gender-affirming care for years. That clinical context matters. Physicians who specialize in this area are more likely to use compounded preparations, particularly injectable estradiol valerate or cypionate, because the doses and delivery vehicles they prefer are not always available in standard branded SKUs.

Jenner was born in 1949, making her 75 at the time this article was published. Age is a direct clinical input. The Endocrine Society's 2017 guideline notes that older transgender women may require individualized dose adjustments because of altered pharmacokinetics and a heightened baseline cardiovascular risk profile. [1]

Why Age Shapes the Protocol

Estrogen increases venous thromboembolism (VTE) risk. A 2019 cohort study of 2,671 transgender women published in BMJ found a VTE incidence of 4.1 per 1,000 person-years, well above the cisgender male rate of 1.4 per 1,000, with oral ethinyl estradiol driving most of that signal. [2] Transdermal or injectable 17-beta estradiol carries a lower clot risk than oral synthetic estrogens. For a 75-year-old, any prescribing clinician would weigh that tradeoff carefully.

The Standard Feminizing HRT Protocol: What Guidelines Actually Specify

The Endocrine Society's 2017 Clinical Practice Guideline recommends 17-beta estradiol as the preferred estrogen for feminizing therapy, explicitly discouraging the use of ethinyl estradiol because of its disproportionate VTE risk. [1] The guideline targets a serum estradiol level of 100 to 200 pg/mL and a serum testosterone level below 50 ng/dL.

Estradiol: The Core Hormone

Three delivery routes dominate U.S. Prescribing for transgender women:

• Oral 17-beta estradiol (Estrace, generics): 2 to 6 mg/day. Inexpensive, widely available, first-pass hepatic metabolism limits bioavailability and raises SHBG.
• Transdermal estradiol patch (Vivelle-Dot, Climara, generics): 0.1 to 0.4 mg/day. Bypasses first-pass metabolism; lower VTE risk than oral routes per the 2019 BMJ cohort. [2]
• Injectable estradiol valerate or cypionate: 5 to 20 mg IM every 1 to 2 weeks. Not available as an FDA-approved branded product for this indication in the U.S., which means compounding is the only route to obtain it in injectable form.

That last point is significant. Injectable estradiol is widely preferred by transgender women because it produces stable, predictable serum levels without the first-pass effect. Because no branded injectable product exists for this specific use, any patient on injections is, by definition, using a compounded preparation. [3]

Anti-Androgens: Blocking Testosterone

The two most prescribed anti-androgens in U.S. Transgender women are spironolactone (an aldosterone antagonist with androgen-blocking properties) and bicalutamide (an androgen receptor antagonist). Spironolactone at 100 to 200 mg/day is considered first-line in most U.S. Centers. [1] Bicalutamide 25 to 50 mg/day is an off-label alternative with a cleaner side-effect profile for some patients.

Both drugs are available as cheap generics. Compounding is rarely necessary for the anti-androgen component alone.

Progesterone: Optional but Increasingly Common

Micronized progesterone (Prometrium 100 to 200 mg at bedtime) is sometimes added to feminizing regimens, though evidence for its benefit in transgender women remains limited. A 2019 survey published in Transgender Health found that roughly 26% of transgender women surveyed were taking some form of progesterone. [4] The Endocrine Society guideline does not mandate progesterone but notes it may improve breast development outcomes in some patients, a claim supported by limited observational data, not randomized trial evidence. [1]

Compounded progesterone (as a cream or troche) is popular in this space because it allows dose customization and avoids peanut oil, the carrier in Prometrium that causes issues for patients with nut allergies.

Compounded vs. Branded HRT: The Clinical Tradeoffs

Compounded hormone preparations are not FDA-approved, which means they have not undergone the same pre-market efficacy and safety review as branded drugs. That is a meaningful distinction, not a minor technicality.

What Compounding Offers

Compounded preparations can be customized in dose, route, and formulation in ways that branded products cannot match. For transgender women specifically, compounding enables:

1. Injectable estradiol valerate or cypionate (no branded equivalent exists in the U.S. For this use)
2. Dose increments smaller or larger than branded options offer
3. Combination creams (estradiol plus progesterone in a single application)
4. Allergen-free carriers for patients who react to ingredients in branded formulations

The FDA acknowledges the legitimate role of compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act for patients whose needs cannot be met by an approved product. [5]

What Compounding Lacks

FDA-approved branded products (Vivelle-Dot, Climara, Estrace, Prometrium) have standardized potency, sterility testing (for injectables), and shelf-life validation. A 2001 study and subsequent FDA analyses found potency variability in compounded hormone preparations ranging from 74% to 149% of the labeled dose. [6] That variability matters when the clinical target is a specific serum estradiol level.

The Endocrine Society guideline states: "We recommend against the use of compounded bioidentical hormones because of the lack of rigorous safety and efficacy data." [1] The North American Menopause Society (NAMS) issued a similar position statement, advising that FDA-approved products should be used preferentially when they meet the patient's clinical needs. [7]

Where Compounding Is Clinically Justified

The guideline caveat is key: "when they meet the patient's clinical needs." For injectable estradiol, where no branded option exists, compounding is not an inferior alternative. It is the only option. A patient who requires injectable estradiol cypionate 20 mg/mL cannot be switched to a branded product because none exists. That alone makes compounding standard of care for a meaningful subset of transgender women.

HealthRX Clinical Framework: Compounded vs. Branded Decision in Transgender Women's HRT

| Clinical Scenario | Branded Option Available? | Compounding Justified? | |---|---|---| | Oral estradiol 2 mg/day | Yes (Estrace, generics) | Low justification | | Transdermal patch 0.1 mg | Yes (Vivelle-Dot, Climara) | Low justification | | Injectable estradiol valerate/cypionate | No U.S. Branded product | High justification | | Micronized progesterone 100 mg | Yes (Prometrium) | Moderate (allergy, dose) | | Custom-dose estradiol cream | No exact match | Moderate justification | | Spironolactone 100 mg | Yes (generics) | Low justification |

What Protocol Caitlyn Jenner's Profile Points To

No physician has disclosed Jenner's actual protocol, and no clinical records are public. What follows is inference grounded in prescribing patterns, age-specific risk data, and her own public statements.

The Age-and-Risk Calculus

At 75, Jenner falls into the age group where transdermal or injectable estradiol is strongly preferred over oral preparations. The 2019 BMJ cohort study showed that transdermal estradiol was associated with a VTE hazard ratio of 1.9 compared to 4.1 for oral estradiol in transgender women, a near doubling of risk reduction from route switching alone. [2] A clinician managing a 75-year-old with a multi-decade hormone history would be unlikely to keep her on oral estradiol.

Public Statements and Lifestyle Signals

Jenner has described an active lifestyle, including golf and outdoor sports. That activity level is consistent with reasonable cardiovascular health, which would allow higher target estradiol levels than a sedentary patient of the same age. She has also described working with physicians she trusts over long periods, a pattern consistent with access to boutique or concierge-style practices that are more likely to compound.

Most Probable Protocol (Inference Only)

Based on the clinical literature and standard-of-care guidelines, the most probable regimen for a 75-year-old transgender woman with Jenner's profile and access to specialized care is:

• Estradiol: Transdermal patch (Vivelle-Dot 0.1 mg twice weekly) or compounded injectable estradiol cypionate 5 to 10 mg IM every 2 weeks, targeting serum estradiol of 100 to 150 pg/mL
• Anti-androgen: Spironolactone 50 to 100 mg/day (dose often reduced in older patients due to hyperkalemia risk) or bicalutamide 25 mg/day
• Progesterone: Micronized progesterone 100 mg at bedtime (Prometrium or compounded equivalent), if tolerated and desired
• Monitoring: Serum estradiol, testosterone, potassium, liver enzymes, lipids, and bone density per Endocrine Society annual monitoring recommendations [1]

The compounded injectable route is genuinely plausible here. Older transgender women with long-term HRT experience often prefer injections for the consistent serum levels and the sense of autonomy they provide. No branded product competes in that space.

Safety Monitoring in Long-Term Feminizing HRT

Long-term estrogen use in transgender women requires structured monitoring. The Endocrine Society recommends laboratory assessment every 3 months during the first year, then annually once stable targets are reached. [1]

Cardiovascular and VTE Risk

The 2019 BMJ cohort (N=2,671 transgender women, N=1,641 transgender men, N=36,530 cisgender controls) found that transgender women had a higher VTE risk than cisgender men (HR 4.0, 95% CI 2.3 to 6.9) and cisgender women (HR 2.0, 95% CI 1.4 to 2.7). [2] That risk may be partially route-dependent. Transdermal estradiol, which avoids hepatic first-pass effects on clotting factor synthesis, is now the preferred route for older patients and those with cardiovascular risk factors.

Bone Density

Estrogen maintains bone density. Transgender women who maintain adequate estradiol levels generally preserve bone mass at rates similar to cisgender women. A 2018 study in the Journal of Clinical Endocrinology and Metabolism (N=711) found that transgender women maintained lumbar spine bone mineral density after 2 years of estrogen therapy, while those with inadequate estrogen levels showed loss. [8] Annual DEXA scans are standard for patients over 65 regardless of gender identity.

Breast Cancer Screening

The Endocrine Society recommends following age-appropriate breast cancer screening guidelines for transgender women on long-term estrogen. A 2019 cohort study published in BMJ found that the breast cancer incidence in transgender women fell between cisgender male and cisgender female rates, arguing for individualized screening rather than blanket exclusion from standard protocols. [9]

The Branded vs. Compounded Debate in Context

The debate over compounded versus branded HRT is not unique to transgender women. It mirrors the broader controversy over bioidentical hormone therapy in menopausal cisgender women, where patient demand for customized preparations has outpaced the clinical evidence base.

What the FDA and NAMS Actually Say

The FDA's 2020 consumer update on compounded hormone therapy states that compounded products "may not meet the same standards as FDA-approved drugs" and that patients should discuss risks with their provider before choosing compounded over approved alternatives. [5] The North American Menopause Society's 2021 position statement echoes that preference for FDA-approved products, while acknowledging that compounding fills genuine gaps for patients with documented clinical needs. [7]

Where the Evidence Gap Lives

The honest answer is that randomized controlled trial data specifically comparing compounded versus branded estradiol in transgender women does not exist. The comparison relies on pharmacokinetic studies, potency-variability data, and observational cohorts. That evidence gap does not make compounded preparations categorically unsafe. It means the risk-benefit conversation has to happen between patient and clinician based on individual need, not population-level averages.

How HealthRX Approaches HRT Decisions for Transgender Women

HealthRX clinicians follow the 2017 Endocrine Society Clinical Practice Guideline as the primary reference, supplemented by the WPATH Standards of Care Version 8 (2022). [1, 10] Branded FDA-approved products are offered as the default when they meet the patient's clinical needs. Compounded preparations are prescribed when:

1. The needed route of administration has no branded equivalent (injectable estradiol)
2. The patient has documented allergies or intolerances to excipients in branded products
3. Dose customization is clinically necessary and cannot be achieved by splitting or combining available branded doses

Serum estradiol is checked 6 to 8 weeks after any dose change to confirm the target range of 100 to 200 pg/mL is met, per Endocrine Society targets. Testosterone is checked simultaneously to confirm suppression below 50 ng/dL. [1]